SPHK1 and ovarian carcinoma: In this regard, we reported that in A2780 human ovarian carcinoma cells resistant to the synthetic retinoid N‐(4‐hydroxyphenyl) retinamide (HPR) SK1 activity, mRNA and protein levels were increased and treatment with an SK inhibitor resulted in increased sensitivity to HPR (Illuzzi et al., 2010).